While regulatory T cells (Tregs) are important for preventing autoimmune responses against healthy tissues, they can also suppress immune responses against cancer cells and, as a result, allow tumors to thrive. To address the potentially pro-cancer activity of Tregs, Dr. Alexander Rudensky is evaluating a Treg-depleting drug called KW-0761, and through an early phase clinical trial his team seeks to determine the appropriate dose and potential effectiveness of KW-0761. Ideally, these studies will lead to a better understanding of the role Tregs play in promoting cancer progression and help assess how well this Treg-depletion strategy works as a novel cancer immunotherapy.
Projects and Grants
Immunoregulatory correlates of a phase I/II study of mogamulizumab (KW-0761) in subjects with advanced and/or metastatic solid tumors
Memorial Sloan Kettering Cancer Center | All Cancers | 2014
Let's spread the word about Immunotherapy! Click to share this page with your community.